Clinical Trial Update: An Open-Label Phase 2 Study of N-Acetyl-D-Mannosamine (ManNAc) in Subjects With Primary Focal Segmental Glomerulosclerosis [Phase 2]

View source ↗

Summary

Open-label Phase 2 trial evaluating N-Acetyl-D-Mannosamine (ManNAc) in subjects with Primary Focal Segmental Glomerulosclerosis; currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Focal Segmental Glomerulosclerosis

Drugs mentioned

• N-Acetyl-D-Mannosamine (ManNAc) (N-Acetyl-D-Mannosamine)

Snippet

Sponsor: National Human Genome Research Institute (NHGRI) | Conditions: Focal Segmental Glomerulosclerosis | Phase 2 | Status: RECRUITING